Shares advanced in Asia on Monday, a day ahead of U.S. President Donald Trump’s deadline for imposing higher tariffs on goods ...

Gilead Sciences Inc.’s (GILD) shares jumped 8.3% after posting second-quarter 2025 adjusted earnings of $2.01 per share, surpassing the Zacks Consensus Estimate of $1.95 per share. Shares of The Trade ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Gilead Sciences Up Over 8%, on Track for Highest Close Since June 2015 — Data Talk Gilead Sciences, Inc. (GILD) is currently at $119.75, up $9.47 or 8.59% --Would be highest close since June 25, 2015, ...

Needham upgraded Gilead stock to buy today. The analyst sees billion-dollar potential in Gilead's Yeztugo drug for preventing HIV. Gilead stock looked cheap before the upgrade. It could be an even ...

How Gilead is helping innovate HIV prevention, removing stigma and empowering Black women. By Spenser Mestel This story was created in paid partnership with Gilead Sciences. Pre-exposure ...

“The agreement between Gilead Sciences and the Global Fund is based on our shared intention to benefit as many people as possible, as quickly as possible with this breakthrough in HIV prevention,” ...

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.